Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 6866

  • Filters activated: Field: Title/Abstract. Clear all
1.

Regenerative and Transplantation Medicine: Cellular Therapy Using Adipose Tissue-Derived Mesenchymal Stromal Cells for Type 1 Diabetes Mellitus.

Takahashi H, Sakata N, Yoshimatsu G, Hasegawa S, Kodama S.

J Clin Med. 2019 Feb 15;8(2). pii: E249. doi: 10.3390/jcm8020249. Review.

PMID:
30781427
2.

Insulin pump therapy, pre-pump HbA1c and metabolic improvement in children with type 1 diabetes at a tertiary Canadian children's hospital.

Botros S, Islam N, Hursh B.

Pediatr Diabetes. 2019 Feb 18. doi: 10.1111/pedi.12834. [Epub ahead of print]

PMID:
30779269
3.

Assessment of optimal insulin administration timing for standard carbohydrates rich meals using continuous glucose monitoring in children with type 1 diabetes-crossover randomized study.

Tucholski K, Sokołowska M, Tucholska D, Kamińska H, Jarosz-Chobot P.

J Diabetes Investig. 2019 Feb 15. doi: 10.1111/jdi.13027. [Epub ahead of print]

4.

Carbohydrate Requirement for Exercise in Type 1 Diabetes: Effects of Insulin Concentration.

Francescato MP, Ajčević M, Accardo A.

J Diabetes Sci Technol. 2019 Feb 15:1932296819826962. doi: 10.1177/1932296819826962. [Epub ahead of print]

PMID:
30767503
5.

Review of Leipzig protocol for intravenous insulin infusion in pediatric patients with type 1 diabetes during intercurrent illness and surgery.

Thiele AG, Heckenmüller M, Bartelt H, Klamt S, Kiess W, Kapellen TM.

Pediatr Diabetes. 2019 Feb 13. doi: 10.1111/pedi.12830. [Epub ahead of print]

PMID:
30761697
6.

Mini Review/Commentary: Growth Hormone Treatment in Children with Type 1 Diabetes.

Bonfig W, Holl RW.

Int J Mol Sci. 2019 Feb 12;20(3). pii: E772. doi: 10.3390/ijms20030772.

7.

[The Impact of Prolonged Use of Continuous Subcutaneous Insulin Infusion in the Control of Type-1 Diabetes].

Azevedo S, Saraiva J, Caramelo F, Fadiga L, Barros L, Baptista C, Melo M, Gomes L, Carrilho F.

Acta Med Port. 2019 Feb 1;32(1):17-24. doi: 10.20344/amp.10778. Epub 2019 Feb 1. Portuguese.

8.

Empagliflozin as an adjunctive therapy for type 1 diabetes.

MacIsaac RJ, Lee MH, McAuley SA, Ward GM, O'Neal DN.

Ann Transl Med. 2018 Dec;6(Suppl 2):S134. doi: 10.21037/atm.2018.12.52. No abstract available.

9.

Basal insulin reductions in anticipation of multiple exercise sessions in people with type 1 diabetes-a clinical perspective.

McCarthy O, Bain SC, Deere R.

Ann Transl Med. 2018 Dec;6(Suppl 2):S111. doi: 10.21037/atm.2018.11.63. No abstract available.

10.

Incorporating Long-Acting Insulin Glargine into the UVA/ Padova Type 1 Diabetes Simulator for In Silico Testing of MDI Therapies.

Visentin R, Schiavon M, Giegerich C, Klabunde T, Dalla Man C, Cobelli C.

IEEE Trans Biomed Eng. 2019 Feb 6. doi: 10.1109/TBME.2019.2897851. [Epub ahead of print]

PMID:
30735983
11.

Cost-Effectiveness of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Patients with Poorly Controlled Type 2 Diabetes in Finland.

Roze S, Smith-Palmer J, Delbaere A, Bjornstrom K, de Portu S, Valentine W, Honkasalo M.

Diabetes Ther. 2019 Feb 7. doi: 10.1007/s13300-019-0575-9. [Epub ahead of print]

PMID:
30730036
12.

Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study.

Braffett BH, Dagogo-Jack S, Bebu I, Sivitz WI, Larkin M, Kolterman O, Lachin JM; DCCT/EDIC Research Group.

Diabetes Care. 2019 Feb 6. pii: dc181574. doi: 10.2337/dc18-1574. [Epub ahead of print]

PMID:
30728218
13.

Development and Assessment of a Mobile Health Application for Monitoring the Linkage Among Treatment Factors of Type 1 Diabetes Mellitus.

Bellei EA, Biduski D, Lisboa HRK, De Marchi ACB.

Telemed J E Health. 2019 Feb 6. doi: 10.1089/tmj.2018.0329. [Epub ahead of print]

PMID:
30724717
14.
15.

Basal-bolus or premixed? Shedding light on optimal insulin regime for type 1 diabetes.

Louise Walton E.

Biomed J. 2018 Dec;41(6):337-339. doi: 10.1016/j.bj.2018.12.008. Epub 2019 Jan 18.

16.

Accumulation of advanced glycation end products in the skin is accelerated in relation to insulin resistance in people with Type 1 diabetes mellitus.

Uruska A, Gandecka A, Araszkiewicz A, Zozulinska-Ziolkiewicz D.

Diabet Med. 2019 Feb 1. doi: 10.1111/dme.13921. [Epub ahead of print]

PMID:
30706538
17.

Cytokine and Adhesion Molecule Expression Induced by Different Strains of Staphylococcus aureus in Type 1 Diabetic Rats: Role of Insulin.

de Souza PRK, Ferreira SS, Nunes FPB, Casagrande FB, Tessaro FHG, Silva MCF, Cruz JWMC, Mamizuka EM, Martins JO.

Front Immunol. 2019 Jan 17;9:3165. doi: 10.3389/fimmu.2018.03165. eCollection 2018.

18.

Real-World Costs of Continuous Insulin Pump Therapy and Multiple Daily Injections for Type 1 Diabetes: A Population-Based and Propensity-Matched Cohort From the Swedish National Diabetes Register.

Toresson Grip E, Svensson AM, Miftaraj M, Eliasson B, Franzén S, Gudbjörnsdottir S, Steen Carlsson K.

Diabetes Care. 2019 Jan 31. pii: dc181850. doi: 10.2337/dc18-1850. [Epub ahead of print]

PMID:
30705062
19.

Vitamin B complex supplementation as a homocysteine-lowering therapy for early stage diabetic nephropathy in pediatric patients with type 1 diabetes: A randomized controlled trial.

Elbarbary NS, Ismail EAR, Zaki MA, Darwish YW, Ibrahim MZ, El-Hamamsy M.

Clin Nutr. 2019 Jan 17. pii: S0261-5614(19)30008-1. doi: 10.1016/j.clnu.2019.01.006. [Epub ahead of print]

PMID:
30704890
20.

Higher rates of large-for-gestational-age newborns mediated by excess maternal weight gain in pregnancies with Type 1 diabetes and use of continuous subcutaneous insulin infusion vs multiple dose insulin injection.

Hauffe F, Schaefer-Graf UM, Fauzan R, Schohe AL, Scholle D, Sedlacek L, Scherer KA, Klapp C, Ramsauer B, Henrich W, Schlembach D, Abou-Dakn M.

Diabet Med. 2019 Feb;36(2):158-166. doi: 10.1111/dme.13861.

PMID:
30698863

Supplemental Content

Loading ...
Support Center